Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Public ClinicalTrials.gov record NCT06533579. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Study identification
- NCT ID
- NCT06533579
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Vironexis Biotherapeutics Inc.
- Industry
- Enrollment
- 32 participants
Conditions and interventions
Conditions
- B-cell Acute Lymphoblastic Leukemia
- Burkitt Lymphoma
- Chronic Lymphocytic Leukemia
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- High-grade B-cell Lymphoma
- Large B-cell Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Mixed Phenotype Acute Leukemia
- Non Hodgkin Lymphoma
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Small Lymphocytic Lymphoma
Interventions
- Dose Level 1, VNX-101 Genetic
- Dose Level 2, VNX-101 Genetic
- Dose Level 3, VNX-101 Genetic
- Dose Level 4, VNX-101 Genetic
Genetic
Eligibility (public fields only)
- Age range
- 13 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 29, 2025
- Primary completion
- May 31, 2027
- Completion
- Aug 31, 2031
- Last update posted
- Mar 29, 2026
2025 – 2031
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | Recruiting |
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | Recruiting |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | Recruiting |
| New York Medical College | Valhalla | New York | 10595 | Recruiting |
| University of North Carolina at Chapel Hill/ University of North Carolina Medical Center | Chapel Hill | North Carolina | 27599 | Recruiting |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | Recruiting |
| Oregon Health & Science University | Portland | Oregon | 97239 | Recruiting |
| TriStar BMT | Nashville | Tennessee | 37203 | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06533579, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 29, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06533579 live on ClinicalTrials.gov.